DRDmitriy A. Reshchikov

Dmitriy A. Reshchikov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dmitriy A. Reshchikov has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evolution of treatments for L-aromatic amino acid decarboxylase deficiency: from symptomatic therapy to precision intraputamenal gene therapy

    by D. A. Reshchikov, S. V. Mikhailova, E. E. Petryaikina, E. A. Putilina, S. V. Gorelikov, E. Yu. Zakharova, K. K. Gadzhieva, Д. А. Рещиков, С. В. Михайлова, Е. Е. Петряйкина, et al.

    L-aromatic amino acid decarboxylase deficiency (AADC) is a rare autosomal recessive neurometabolic disorder caused by biallelic versions in the DDC gene and resulting in severe dopamine and serotonin deficiency Until recently, treatment was limited to exclusively symptomatic approaches and did not influence the poor prognosis. This review provides a chronological reconstruction of the development of therapeutic strategies, from early ineffective pharmacological regimens to modern pathogenetic gene therapy using the recombinant adeno-associated viral vector AAV2hAADC. Particular attention is paid to the neurosurgical component: the transition from frame stereotaxy and isolated intraputamenal infusion to contactless neuronavigation and convection-enhanced delivery under MRI guidance. The Russian experience of implementing a frameless stereotactic technique at the Russian Children’s Clinical Hospital is separately reviewed. Key clinical studies confirming the efficacy and safety of the approach are discussed, as are regulatory milestones leading to the approval of eladocagen exuparvovec (Upstaza in Europe in 2022, Kebilidi in the USA in 2024) Prospects and unresolved issues, including the optimal therapeutic window and long-term safety, are addressed.

  • Open Access

    Practical aspects of intracerebroventricular infusions of cerliponase alfa in patients with neuronal ceroid lipofuscinosis type 2

    by Svetlana V. Mikhaylova, Михайлова Светлана Витальевна, V. S. Lobanova, Лобанова В. С., D. A. Reshchikov, Рещиков Д. А., P. V. Lobankin, Лобанкин П. В.

    Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare, autosomal recessive neurodegenerative disorder caused by mutations in the TPP1 gene, which lead to a decrease or complete loss of lysosomal tripeptidyl peptidase 1 enzyme activity. The classic form of CLN2 disease typically manifests between the ages of 2 and 4 years. Over time, there is a rapid and predictably severe progression of intellectual and motor deficits, loss of visual acuity, and an increased frequency of epileptic seizures refractory to antiepileptic therapy. In its natural course, the classic form of CLN2 disease leads to severe disability by 6–7 years of age and death on average during the 10th year of life. Currently, pathogenetic enzyme replacement therapy has been developed only for CLN2 disease, utilizing the drug cerliponase alfa. In Russia, children with CLN2 disease are provided with cerliponase alfa through funding from the “Circle of Kindness”, a state fund supporting children with severe life-threatening and chronic diseases, including rare (orphan) conditions. Cerliponase alfa cannot cross the blood-brain barrier and must be administered directly into the cerebrospinal fluid via intracerebroventricular (ICV) infusion through a surgically implanted reservoir and ventricular catheter. Infectious complications can result in missed ICV infusions, which, in turn, may adversely affect the efficacy of enzyme replacement therapy. To reduce the risk of infectious complications, strict adherence to aseptic rules is essential during patient preparation, as well as during and after the ICV infusion. These practical guidelines for performing ICV infusions of enzyme replacement therapy in patients with CLN2 disease have been developed to implement measures in clinical practice aimed at minimizing the risk of infectious complications and damage to ICV infusion devices.

  • Open Access

    Frameless stereotactic infusion of gene therapy into the putamen for AADC deficiency in children: technical and organizational aspects of implementation in Russia

    by Dmitriy A. Reshchikov, R. B. Mai, S. V. Mikhaylova, S. V. Gorelikov, Е. Yu. Zakharova, E. E. Petryaykina, E. A. Putilina, V. V. Palm

    Aim. To present the authors’ experience in implementing a frameless stereotactic infusion technique of a gene preparation using an adeno-associated vectored virus into the subcortical structures of the brain in children with aromatic L-amino acid decarboxylase deficiency (AADCd), with an emphasis on technical and organizational aspects. Materials and methods. From November 2024 to December 2025, six bilateral infusions of eladocagen exuparvovec (Upstaza®) were administered into the putamen of children with genetically confirmed AADCd in the Department of Pediatric Neurosurgery of the Russian Children’s Clinical Hospital. The key stages of patient selection, regulatory support, preoperative planning based on brain magnetic resonance imaging data, features of frameless navigation, the Z-shaped convection-enhanced infusion technique, and measures for preventing intra- and postoperative complications are described. The analysis of clinical outcomes is deliberately not presented in this work and is planned for a separate publication after increasing the sample size and follow-up observation. Results. In all 6 cases, accurate drug delivery to the putamen was ensured in accordance with preoperative planning, and no intraoperative complications were observed. Early postoperative magnetic resonance imaging monitoring revealed no clinically significant hemorrhagic or ischemic brain damage. In all cases, improvements in motor and autonomic symptoms of varying severity were noted during the first months of follow-up. Conclusion. The presented experience demonstrates the technical feasibility and safety of frameless stereotactic gene therapy for AADCd in children in a Federal Center setting. The proposed method can serve as the basis for a national treatment protocol for AADCd and the establishment of a reference center for gene therapy for central nervous system diseases.


  • Open Access

    Frameless intraputaminal delivery of gene therapy with eladocagene exuparvovec in patients with aromatic L-amino acid decarboxylase deficiency: safe and efficient results

    by Roni Mai, Dmitriy Reshchikov, Vladimir Popov, Sergey Gorelikov, Ekaterina Zakharova, Svetlana Mikhaylova

    Purpose: We present two clinical cases of frameless, neuronavigated gene therapy with eladocagene exuparvovec for aromatic L-amino acid decarboxylase (AADC) deficiency in pediatric patients, detailing the targeted bilateral microdose delivery of viral vectors into the putamen and highlighting the feasibility and challenges of this approach in managing a rare neurometabolic disorder. Methods: Two patients with a confirmed diagnosis of AADCD underwent frameless stereotactic gene therapy. High-resolution 3 T MRI-guided trajectories were planned for the targeted bilateral putaminal infusion of 0.32 ml of eladocagene exuparvovec (AAV2-hAADC). The agent was delivered via a SmartFlow Neuro Ventricular Cannula in a “Z-pattern,” retracting the cannula 2 mm every 9 min to achieve controlled microdosing. Results: Accurate frameless drug delivery was achieved in a shorter time than frame-based approaches, with no intraoperative or postoperative complications. One patient showed a small post-ischemic cyst on the 1-month follow-up MRI, without any neurological deficits. Over 2 months, both patients demonstrated reduced oculogyric crises, diminished hyperkinesis, and improved head control, with no significant adverse events. Conclusion: Frameless, neuronavigated gene therapy for AADC deficiency proved both feasible and safe, with early clinical improvements observed in motor function and symptom control. This technique offers a promising alternative to frame-based methods and expands treatment options for this rare neurometabolic disorder.


  • Diagnosis and evaluation of the effectiveness of surgical methods for treating non-syndromic isolated craniosynostosis in children over 2 years old using the example of scaphocephaly and frontal plagiocephaly

    by D.A. Reshchikov, A.V. Lopatin, S.A. Yasonov, I.G. Vasilyev, A.Yu. Kugushev, E.V. Shchepkina, Moscow Russian Presidential Academy Of National Economy And Public Administration (Ranepa)

  • RUSSIAN INTERDISCIPLINARY CONSENSUS ON ACHONDROPLASIA (APPROVED BY THE EXPERT COUNCIL IN JAN. 2023)

    by A.I. Asmanov, N.D. Vashakmadze, V.A. Vilensky, V.Yu. Voinova, I.G. Vorontsova, I.S. Dantsev, N.V. Zhurkova, T.N. Kekeyeva, V.M. Kenis, T.T. Knyazeva, et al.

    Вам открыли доступ к файлу. Отправлено с помощью Облако Mail.ru.


  • Open Access

    Principles of the differential diagnosis of achondroplasia and pseudoachondroplasia

    by Tatiana V. Markova, Vladimir M. Kenis, Evgenii V. Melchenko, Dmitry A. Reshchikov, Aynur E. Alieva, Darya V. Osipova, Liudmila A. Bessonova, Tatiana S. Nagornova, Natalya N. Vasserman, Natalya Yu. Ogorodova, et al.

    BACKGROUND: Achondroplasia and pseudoachondroplasia are hereditary systemic skeletal dysplasias characterized by a certain similarity of clinical manifestations; however, they have different etiopathogenetic mechanisms and confirmation methods for molecular genetic diagnosis. Their common phenotypic features often make differential diagnosis difficult during the clinical examination of patients, planning DNA diagnostics, and appropriate time detection of neurosurgical and orthopedic complications. AIM: This study aimed to identify differential diagnostic criteria for achondroplasia and pseudoachondroplasia and optimize the strategy for their molecular genetic diagnosis. MATERIALS AND METHODS: A comprehensive examination of 76 children from 74 unrelated families aged 1 month to 18 years with phenotypic signs of achondroplasia and pseudoachondroplasia was conducted. To clarify the diagnosis through genealogical and amnestic analysis, clinical and neurological examination data according to the standard method and radiographic data were used. Molecular genetic confirmation of diseases was conducted by searching for hotspot mutations in the FGFR3 gene, assessing the number of GAC repeats located in exon 13 of the COMP gene, and new-generation sequencing of the target panel consisting of 166 genes responsible for hereditary skeletal pathology. RESULTS: Based on a comparative analysis of the specific phenotypic characteristics, the criteria for the differential diagnosis of achondroplasia and pseudoachondroplasia were identified. The leading signs of achondroplasia are disproportionate nanism from birth, macrocrania, and facial dysmorphism, which are not specific to pseudoachondroplasia. Certain radiological features are essential in the differential diagnosis of pseudoachondroplasia, which should be considered when referring to patients for molecular genetic analysis. A deletion of the GAC repeat c.1417_1419del in the COMP gene was identified in 27% of patients with pseudoachondroplasia. Thus, the analyses of these two mutations in FGFR3 and COMP were conducted first. In the absence of target mutations, further diagnostic search should be continued with a target panel consisting of 166 genes responsible for hereditary skeletal pathology or whole-exome sequencing. CONCLUSIONS: The analysis of the clinical, radiological, and molecular genetic characteristics of patients with achondroplasia and pseudoachondroplasia, together with the literature data analysis, made it possible to clarify the differential diagnostic criteria for these diseases and optimize the algorithm for their molecular genetic diagnosis.


  • Open Access

    The use of proton radiation therapy in a patient with melanotic neuroectodermal tumor of infants of the anterior fontanel: description of a clinical case

    by N. D. Faseeva, N. I. Martynova, M. D. Maksimov, K. F. Boyko, N. A. Vorobyev, N. A. Berezina, N. A. Plakhotina, D. A. Reshchikov, I. G. Vasiliev, R. B. Mai, et al.

    Melanotic neuroectodermal tumor (MNET) of infants is a rare benign neoplasm detected mainly in children of the first year of life. Standard therapy consists of radical surgical removal of the tumor. Currently, the treatment of patients with recurrent and unresectable forms of the disease is relevant. The number of publications using polychemotherapy and radiation therapy is extremely limited. This article describes a clinical case of the occurrence of MNET in the anterior fontanel with a recurrent course. Proton radiation therapy was chosen as an alternative treatment method.